0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Preliminary Evaluation of Cycloguanil Pamoate in Dermal Leishmaniasis

Antonio Peña Chavarria, MD, DPH; Emil Kotcher, ScD; Cecilia Lizano, MQC
JAMA. 1965;194(10):1142-1144. doi:10.1001/jama.1965.03090230110039.
Text Size: A A A
Published online

SOME REGRESSION of early lesions of dermal leishmaniasis has been observed by one of the authors (A.P.C.) in malaria patients treated orally with chloroguanide hydrochloride. The extent of improvement in the leishmanial lesions was not great, however, possibly because of the short duration of chloroguanide hydrochloride administration. The antimalarial activity of chloroguanide hydrochloride in man is due mainly to a dihydrotriazine metabolite of the drug.1-5 Cycloguanil pamoate (CI-501; Camolar)6 is a poorly water-soluble salt of this dihydrotriazine. An intramuscular dose of cycloguanil pamoate acts as a repository antimalarial drug in animals6,7 and man.8-11 Therefore, it seemed worthwhile to evaluate the efficacy of cycloguanil pamoate in patients with dermal leishmaniasis, caused by Leishmania braziliensis. This preliminary report gives the results obtained with cycloguanil pamoate in 30 such Costa Rican patients.

Materials and Methods  The patients who received treatment ranged in age from 7 months to 60 years,

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();